Susceptibility to oxidation of plasma low-density lipoprotein in X-linked adrenoleukodystrophy: Effects of simvastatin treatment

Antonella Di Biase, Serafina Salvati, Rosaria Varí, Christina Avellino, Francesco Sforza, Marco Cappa, Roberta Masella

Research output: Contribution to journalArticlepeer-review

Abstract

This paper shows for the first time the higher oxidizability of low-density lipoprotein (LDL) in plasma from adrenoleukodystrophy (ALD) patients compared to that of control subjects. LDL oxidation susceptibility was assessed by conjugate diene formation, hydroperoxide and lipoperoxide formation, and electrophoretic mobility. Simvastatin therapy, an HMG-CoA reductase inhibitor, seems to be a protective pharmacological agent against the higher oxidizability of LDL in plasma from ALD patients.

Original languageEnglish
Pages (from-to)651-655
Number of pages5
JournalMolecular Genetics and Metabolism
Volume71
Issue number4
DOIs
Publication statusPublished - 2000

Keywords

  • Adrenoleukodystrophy
  • Adrenomyeloneuropathy
  • Asymptomatic
  • Low-density lipoprotein
  • Oxidizability
  • Simvastatin

ASJC Scopus subject areas

  • Biochemistry
  • Genetics
  • Endocrinology, Diabetes and Metabolism

Fingerprint Dive into the research topics of 'Susceptibility to oxidation of plasma low-density lipoprotein in X-linked adrenoleukodystrophy: Effects of simvastatin treatment'. Together they form a unique fingerprint.

Cite this